MB07811

DB05192InvestigationalSmall molecule

MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. MB07811, a small molecule that is administered orally, has... MB07811, a small molecule that is administered orally, has been extensively studied preclinically and is currently undergoing clinical testing.

Mechanism: Studies indicate that targeting TR agonists to the liver has the potential to lower both LDL-cholesterol (the "bad" cholesterol) and both hepatic and plasma triglyceride levels.
Curator reviewed
Primary indication: Investigated for use/treatment in hyperlipidemia.Curator reviewed
Code names: MB07811

Resolves to

Targets

P10828THRB

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with MB07811, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account